Cargando…

Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice

BACKGROUND: Hepatic mitochondrial dysfunction plays an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Methyl donor supplementation has been shown to alleviate NAFLD, connecting the condition to the one-carbon metabolism. Thus, the objective was to investigate regula...

Descripción completa

Detalles Bibliográficos
Autores principales: Berge, Rolf K., Bjørndal, Bodil, Strand, Elin, Bohov, Pavol, Lindquist, Carine, Nordrehaug, Jan Erik, Svardal, Asbjørn, Skorve, Jon, Nygård, Ottar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743328/
https://www.ncbi.nlm.nih.gov/pubmed/26846427
http://dx.doi.org/10.1186/s12944-016-0192-9
_version_ 1782414344217165824
author Berge, Rolf K.
Bjørndal, Bodil
Strand, Elin
Bohov, Pavol
Lindquist, Carine
Nordrehaug, Jan Erik
Svardal, Asbjørn
Skorve, Jon
Nygård, Ottar
author_facet Berge, Rolf K.
Bjørndal, Bodil
Strand, Elin
Bohov, Pavol
Lindquist, Carine
Nordrehaug, Jan Erik
Svardal, Asbjørn
Skorve, Jon
Nygård, Ottar
author_sort Berge, Rolf K.
collection PubMed
description BACKGROUND: Hepatic mitochondrial dysfunction plays an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Methyl donor supplementation has been shown to alleviate NAFLD, connecting the condition to the one-carbon metabolism. Thus, the objective was to investigate regulation of homocysteine (Hcy) and metabolites along the choline oxidation pathway during induction of hepatic steatosis by the fatty acid analogue tetradecylthiopropionic acid (TTP), an inhibitor of mitochondrial fatty acid oxidation. METHODS: Mice were fed a control diet, or diets containing 0.3 %, 0.6 %, or 0.9 % (w/w) TTP for 14 days. Blood and liver samples were collected, enzyme activities and gene expression were analyzed in liver, lipid and fatty acid composition in liver and plasma, one-carbon metabolites, B-vitamin status, carnitine and acylcarnitines were analyzed in plasma. RESULTS: Liver mitochondrial fatty acid oxidation decreased by 40 % and steatosis was induced in a dose dependent manner; total lipids increased 1.6-fold in animals treated with 0.3 % TTP, 2-fold with 0.6 % TTP and 2.1 fold with 0.9 % TTP compared to control. The higher hepatic concentration of fatty acids was associated with shortening of carbon-length. Furthermore, the inhibited fatty acid oxidation led to a 30-fold decrease in plasma carnitine and 9.3-fold decrease in acetylcarnitine at the highest dose of TTP, whereas an accumulation of palmitoylcarnitine resulted. Compared to the control diet, TTP administration was associated with elevated plasma total Hcy (control: 7.2 ± 0.3 umol/L, 0.9 % TTP: 30.5 ± 5.9 umol/L) and 1.4-1.6 fold increase in the one-carbon metabolites betaine, dimethylglycine, sarcosine and glycine, accompanied by changes in gene expression of the different B-vitamin dependent pathways of Hcy and choline metabolism. A positive correlation between total Hcy and hepatic triacylglycerol resulted. CONCLUSIONS: The TTP-induced inhibition of mitochondrial fatty acid oxidation was not associated with increased hepatic oxidative stress or inflammation. Our data suggest a link between mitochondrial dysfunction and the methylation processes within the one-carbon metabolism in mice.
format Online
Article
Text
id pubmed-4743328
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47433282016-02-06 Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice Berge, Rolf K. Bjørndal, Bodil Strand, Elin Bohov, Pavol Lindquist, Carine Nordrehaug, Jan Erik Svardal, Asbjørn Skorve, Jon Nygård, Ottar Lipids Health Dis Research BACKGROUND: Hepatic mitochondrial dysfunction plays an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Methyl donor supplementation has been shown to alleviate NAFLD, connecting the condition to the one-carbon metabolism. Thus, the objective was to investigate regulation of homocysteine (Hcy) and metabolites along the choline oxidation pathway during induction of hepatic steatosis by the fatty acid analogue tetradecylthiopropionic acid (TTP), an inhibitor of mitochondrial fatty acid oxidation. METHODS: Mice were fed a control diet, or diets containing 0.3 %, 0.6 %, or 0.9 % (w/w) TTP for 14 days. Blood and liver samples were collected, enzyme activities and gene expression were analyzed in liver, lipid and fatty acid composition in liver and plasma, one-carbon metabolites, B-vitamin status, carnitine and acylcarnitines were analyzed in plasma. RESULTS: Liver mitochondrial fatty acid oxidation decreased by 40 % and steatosis was induced in a dose dependent manner; total lipids increased 1.6-fold in animals treated with 0.3 % TTP, 2-fold with 0.6 % TTP and 2.1 fold with 0.9 % TTP compared to control. The higher hepatic concentration of fatty acids was associated with shortening of carbon-length. Furthermore, the inhibited fatty acid oxidation led to a 30-fold decrease in plasma carnitine and 9.3-fold decrease in acetylcarnitine at the highest dose of TTP, whereas an accumulation of palmitoylcarnitine resulted. Compared to the control diet, TTP administration was associated with elevated plasma total Hcy (control: 7.2 ± 0.3 umol/L, 0.9 % TTP: 30.5 ± 5.9 umol/L) and 1.4-1.6 fold increase in the one-carbon metabolites betaine, dimethylglycine, sarcosine and glycine, accompanied by changes in gene expression of the different B-vitamin dependent pathways of Hcy and choline metabolism. A positive correlation between total Hcy and hepatic triacylglycerol resulted. CONCLUSIONS: The TTP-induced inhibition of mitochondrial fatty acid oxidation was not associated with increased hepatic oxidative stress or inflammation. Our data suggest a link between mitochondrial dysfunction and the methylation processes within the one-carbon metabolism in mice. BioMed Central 2016-02-05 /pmc/articles/PMC4743328/ /pubmed/26846427 http://dx.doi.org/10.1186/s12944-016-0192-9 Text en © Berge et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Berge, Rolf K.
Bjørndal, Bodil
Strand, Elin
Bohov, Pavol
Lindquist, Carine
Nordrehaug, Jan Erik
Svardal, Asbjørn
Skorve, Jon
Nygård, Ottar
Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
title Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
title_full Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
title_fullStr Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
title_full_unstemmed Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
title_short Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
title_sort tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743328/
https://www.ncbi.nlm.nih.gov/pubmed/26846427
http://dx.doi.org/10.1186/s12944-016-0192-9
work_keys_str_mv AT bergerolfk tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT bjørndalbodil tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT strandelin tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT bohovpavol tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT lindquistcarine tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT nordrehaugjanerik tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT svardalasbjørn tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT skorvejon tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice
AT nygardottar tetradecylthiopropionicacidinduceshepaticmitochondrialdysfunctionandsteatosisaccompaniedbyincreasedplasmahomocysteineinmice